3rd Jun 2015 06:52
LONDON (Alliance News) - FTSE 100-listed pharmaceutical company Shire PLC said Wednesday that the European Medicines Agency has approved Resolor for the use in male adults for the treatment of chronic constipation in whom laxatives fail to provide adequate relief.
Resolor is approved for use in women in Europe, so this approval extends the use of the treatment to male patients.
"The extension of the Resolor label to include use in men is an important development in the treatment of chronic constipation," said Roger Adsett, head of Shire's Gastrointestinal and Internal Medicines business.
"We are pleased to now be able to offer the benefits of Resolor to even more chronic constipation patients in need of treatment options," Adsett added.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Shire